Waverly Advisors LLC Purchases 37,143 Shares of Novo Nordisk A/S $NVO

Waverly Advisors LLC lifted its position in Novo Nordisk A/S (NYSE:NVO) by 396.5% in the first quarter, HoldingsChannel.com reports. The firm owned 46,510 shares of the company’s stock after acquiring an additional 37,143 shares during the period. Waverly Advisors LLC’s holdings in Novo Nordisk A/S were worth $1,709,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Loomis Sayles & Co. L P boosted its stake in Novo Nordisk A/S by 6.0% during the fourth quarter. Loomis Sayles & Co. L P now owns 17,135,384 shares of the company’s stock worth $871,848,000 after buying an additional 969,916 shares in the last quarter. Franklin Resources Inc. raised its stake in shares of Novo Nordisk A/S by 5.1% in the 4th quarter. Franklin Resources Inc. now owns 14,702,508 shares of the company’s stock valued at $748,064,000 after buying an additional 717,719 shares in the last quarter. Morgan Stanley raised its stake in shares of Novo Nordisk A/S by 3.5% in the 4th quarter. Morgan Stanley now owns 12,842,089 shares of the company’s stock valued at $653,406,000 after buying an additional 428,660 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in shares of Novo Nordisk A/S by 99.7% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 9,688,262 shares of the company’s stock worth $492,940,000 after acquiring an additional 4,836,285 shares during the period. Finally, Arrowstreet Capital Limited Partnership bought a new position in shares of Novo Nordisk A/S during the 1st quarter worth about $287,660,000. 11.54% of the stock is owned by institutional investors.

Key Headlines Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Expanded Wegovy access: Novo Nordisk partnered with Crux to offer simpler benefit designs and more predictable pricing for U.S. employer health plans. The agreement could reduce affordability barriers and broaden access to Wegovy, supporting future prescription growth. Novo Nordisk Teams Up With Crux To Expand Wegovy Access
• Positive Sentiment: Oral Wegovy opportunity: The European Commission’s approval of Novo’s once-daily oral Wegovy pill provides a new growth avenue in obesity treatment. Combined with the U.S. employer-access deal, the developments have encouraged optimism about wider GLP-1 adoption. Novo Nordisk Is Up After EU Wegovy Pill Approval And US Access Deal
• Positive Sentiment: Strong underlying product demand: Analysts expect Ozempic and Wegovy sales to be the primary focus of the upcoming second-quarter report, with oral launches and label expansions potentially supporting continued growth. Broader investor commentary also identifies Novo as a major beneficiary of the expanding GLP-1 market. How Will Ozempic and Wegovy Sales Aid NVO’s Upcoming Q2 Results?
• Neutral Sentiment: Results approaching: Investors are waiting for quarterly evidence that Ozempic and Wegovy sales can offset mounting competitive pressure. The earnings report may be a near-term catalyst, but expectations could also increase volatility if sales, pricing, or guidance disappoint. How Will Ozempic and Wegovy Sales Aid NVO’s Upcoming Q2 Results?
• Negative Sentiment: CagriSema litigation: A U.S. judge allowed parts of a shareholder lawsuit to proceed. Investors allege Novo misled them about a key CagriSema clinical trial, creating legal, reputational, and potential financial risks for the company’s next-generation obesity pipeline. Why Shareholders Are Suing Novo Nordisk Over CagriSema
• Negative Sentiment: Valuation and competition concerns: Commentary argues that much of Novo’s GLP-1 opportunity may already be reflected in the stock, while competitive pressure could limit upside and pricing power. Novo Nordisk: Too Late For A Great Opportunity

Novo Nordisk A/S Trading Down 0.1%

NVO stock opened at $51.55 on Friday. The business has a fifty day moving average price of $46.87 and a 200 day moving average price of $45.49. The company has a debt-to-equity ratio of 0.59, a current ratio of 0.79 and a quick ratio of 0.56. Novo Nordisk A/S has a fifty-two week low of $35.12 and a fifty-two week high of $64.16. The stock has a market capitalization of $230.17 billion, a price-to-earnings ratio of 12.10, a P/E/G ratio of 4.70 and a beta of 0.77.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Tuesday, March 31st. The company reported $1.03 EPS for the quarter. The company had revenue of $10.85 billion for the quarter. Novo Nordisk A/S had a return on equity of 63.31% and a net margin of 37.23%. Analysts expect that Novo Nordisk A/S will post 3.39 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on NVO shares. Citigroup reissued a “neutral” rating on shares of Novo Nordisk A/S in a research note on Monday, July 20th. Wall Street Zen cut shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Saturday, June 20th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Novo Nordisk A/S in a report on Monday, July 20th. Zacks Research lowered Novo Nordisk A/S from a “hold” rating to a “strong sell” rating in a research note on Monday, July 13th. Finally, Nordea Equity Research raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Friday, June 19th. Five research analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, Novo Nordisk A/S presently has an average rating of “Hold” and an average target price of $65.56.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.